| Trial name or title |
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX alone or in combination with AMG 102 or panitumumab as first‐line treatment in patients with advanced gastroesophageal adenocarcinoma |
| Methods |
RCT |
| Participants |
Patients with histologically‐proven adenocarcinoma of the stomach, esophagus or gastro‐esophageal junction; locally‐advanced or metastatic disease; measurable disease (RECIST 1.1); no known HER2 over‐expression; no prior palliative chemotherapy |
| Interventions |
Active comparator: Arm A : simplified FOLFOX 4 (every 2 week); Experimental: Arm B : simplified FOLFOX 4 + panitumumab (every 2 weeks); Experimental: Arm C : simplified FOLFOX 4 + AMG 102 (every 2 weeks ); |
| Outcomes |
PFS rate at 4 months, PFS, OS, time to progression |
| Starting date |
January 2011 |
| Contact information |
Not available |
| Notes |
Phase II. This study is ongoing, but not recruiting participants |
